GB201919019D0 - Antigen-binding domain - Google Patents

Antigen-binding domain

Info

Publication number
GB201919019D0
GB201919019D0 GBGB1919019.8A GB201919019A GB201919019D0 GB 201919019 D0 GB201919019 D0 GB 201919019D0 GB 201919019 A GB201919019 A GB 201919019A GB 201919019 D0 GB201919019 D0 GB 201919019D0
Authority
GB
United Kingdom
Prior art keywords
antigen
binding domain
domain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1919019.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Priority to GBGB1919019.8A priority Critical patent/GB201919019D0/en
Publication of GB201919019D0 publication Critical patent/GB201919019D0/en
Priority to AU2020406862A priority patent/AU2020406862A1/en
Priority to CN202080088886.3A priority patent/CN114828879A/zh
Priority to PCT/GB2020/053289 priority patent/WO2021123810A1/en
Priority to EP20838216.8A priority patent/EP4076509A1/en
Priority to US17/784,392 priority patent/US12496314B2/en
Priority to JP2022537008A priority patent/JP7600240B2/ja
Priority to CA3161844A priority patent/CA3161844A1/en
Priority to JP2024200599A priority patent/JP2025015730A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1919019.8A 2019-12-20 2019-12-20 Antigen-binding domain Ceased GB201919019D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1919019.8A GB201919019D0 (en) 2019-12-20 2019-12-20 Antigen-binding domain
AU2020406862A AU2020406862A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to PSMA
CN202080088886.3A CN114828879A (zh) 2019-12-20 2020-12-18 结合psma的抗原结合结构域
PCT/GB2020/053289 WO2021123810A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to psma
EP20838216.8A EP4076509A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to psma
US17/784,392 US12496314B2 (en) 2019-12-20 2020-12-18 Antigen-binding domain
JP2022537008A JP7600240B2 (ja) 2019-12-20 2020-12-18 Ｐｓｍａに結合する抗原結合ドメイン
CA3161844A CA3161844A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to psma
JP2024200599A JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1919019.8A GB201919019D0 (en) 2019-12-20 2019-12-20 Antigen-binding domain

Publications (1)

Publication Number Publication Date
GB201919019D0 true GB201919019D0 (en) 2020-02-05

Family

ID=69322734

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1919019.8A Ceased GB201919019D0 (en) 2019-12-20 2019-12-20 Antigen-binding domain

Country Status (8)

Country Link
US (1) US12496314B2 (https=)
EP (1) EP4076509A1 (https=)
JP (2) JP7600240B2 (https=)
CN (1) CN114828879A (https=)
AU (1) AU2020406862A1 (https=)
CA (1) CA3161844A1 (https=)
GB (1) GB201919019D0 (https=)
WO (1) WO2021123810A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
KR20250133776A (ko) 2023-02-10 2025-09-08 아뮤닉스 파마슈티컬스, 인크. 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
JPWO2016111344A1 (ja) * 2015-01-08 2017-10-26 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
BR112018070948A2 (pt) * 2016-04-13 2019-01-29 Orimabs Ltd. anticorpos anti-psma e utilização dos mesmos
GB201607968D0 (en) * 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
TWI908706B (zh) * 2018-03-07 2025-12-21 美商波西達治療公司 ＣＡＲＴｙｒｉｎ組成物和使用方法
CN108640999B (zh) 2018-03-27 2021-08-13 广东万海细胞生物科技有限公司 一种靶向表达psma表面抗原的细胞的嵌合抗原受体
CN110526984A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN110526976A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用

Also Published As

Publication number Publication date
WO2021123810A1 (en) 2021-06-24
EP4076509A1 (en) 2022-10-26
CN114828879A (zh) 2022-07-29
JP2023507740A (ja) 2023-02-27
JP2025015730A (ja) 2025-01-30
US12496314B2 (en) 2025-12-16
JP7600240B2 (ja) 2024-12-16
AU2020406862A1 (en) 2022-06-16
CA3161844A1 (en) 2021-06-24
US20240252534A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
GB201709203D0 (en) Antigen-binding domain
SG11202103773TA (en) Binding domain
GB201913258D0 (en) Antigen-binding domain
IL290253A (en) Glycovariants of igm
CA187781S (en) Banquette
CA189677S (en) Uroflowmeter
GB201819434D0 (en) Domain adaptation
CA189795S (en) Handshower
GB201912107D0 (en) Combination
GB201919019D0 (en) Antigen-binding domain
PT3790870T (pt) Compostos de ciclopentano
CA190386S (en) Beverageware
CA189047S (en) Hammock-tent
CA190387S (en) Beverageware
CA190385S (en) Beverageware
CA190384S (en) Beverageware
GB201914847D0 (en) Combination
CA189434S (en) Jerrycan
GB201916855D0 (en) My fairphone
GB201916327D0 (en) Disclosure
GB201916328D0 (en) Disclosure
GB201916329D0 (en) Disclosure
CA187366S (en) Hoodie
CA187077S (en) Velomobile
GB201912214D0 (en) Disclosure

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)